Patient-derived prostate cancer organoids that retain key molecular, histopathological and phenotypic features of human prostate tumors, intended for use as in vitro research models for oncology mechanism study, drug discovery and preclinical exploratory research.
- Overview
- Details
- Advantages
- FAQs
Overview
Prostate cancer is one of the most prevalent malignant tumors in men worldwide. Its progression involves cumulative genetic and epigenetic alterations in prostatic epithelial cells, ranging from prostatic intraepithelial neoplasia (PIN) to localized adenocarcinoma and advanced metastatic disease. Commonly reported molecular alterations include TMPRSS2-ERG gene fusion, PTEN loss, AR (androgen receptor) signaling dysregulation, TP53 mutation, and MYC amplification. Castration-resistant prostate cancer (CRPC) represents a major research focus due to limited effective treatment options in later-stage disease.
Prostate tumors exhibit substantial interpatient heterogeneity, and conventional 2D cell cultures often fail to maintain androgen dependency and lineage-specific phenotypes during long-term passage, limiting their utility for translational research.
Our prostate cancer organoids are derived from patient tumor tissues, including treatment-naïve and post-therapy specimens, and are cultured to preserve the molecular and structural characteristics of the source tissue. These three-dimensional models are designed to support basic and preclinical research on prostate tumor biology, target exploration and therapeutic response assessment.
Key Phenotypic Features of Prostate Cancer Organoids
- Androgen receptor (AR) expression patterns consistent with source tumor tissues
- Preserved common molecular alterations including PTEN loss and TMPRSS2 rearrangements
- Prostatic adenocarcinoma-like glandular architecture and cellular morphology
- Enrichment of tumor cell populations with stemness-associated marker expression
- Distinct proliferation and signaling activity across different tumor grades
- Retained phenotypic diversity between localized and advanced-stage specimens
- Stable androgen-responsive growth in applicable model subsets
These features make the organoids suitable for mechanistic studies, biomarker exploration and preclinical drug candidate evaluation in prostate cancer research.
Fig. 1. Organoids from primary PCa retain features of originating tumor (Pamarthy S, et al., 2021).
Our Prostate Cancer Organoids
Our prostate cancer organoids are cryopreserved, ready-to-use in vitro research models, maintained in defined culture systems to reduce phenotypic variation and support experimental reproducibility.
Core Characteristics
- Specimen diversity: Derived from primary tumors, metastatic sites and different treatment-stage tissues
- Phenotype stability: Optimized androgen-containing/depleted media options to maintain AR status
- Molecular representation: Covers common genetic alterations reported in prostate cancer research
- Experimental compatibility: Adaptable to standard cell-based assay workflows
- Standardized format: Uniform cryovial specifications for consistent experimental seeding
Characterization & Quality Control
All organoids undergo standardized validation to ensure research utility:
- Molecular profiling: Targeted sequencing of selected prostate cancer-associated genes
- Immunophenotyping: Immunostaining validation of AR, PSA, NKX3.1 and proliferation markers
- Morphological assessment: Microscopic confirmation of 3D glandular structure and growth status
- Viability testing: Post-thaw recovery rate ≥80% in routine QC batches
- Biosafety verification: Mycoplasma-negative status and identity confirmation
Research Applications
These organoids are suitable for a range of in vitro prostate cancer research scenarios:
- Mechanism Research: Study of AR signaling, tumor proliferation and cellular heterogeneity.
- Preclinical Drug Screening: Evaluation of small molecule compounds, endocrine therapies and combination regimens.
- Biomarker Exploration: Identification of potential molecular markers associated with drug response.
- Resistance Study: Modeling of phenotypic changes under sustained drug exposure in vitro.
- TME Research: Compatible with stromal cell co-culture for tumor microenvironment studies.
Key Strengths
- Research-relevant phenotypes: Retain key molecular and cellular features of source tumors
- Reduced preparation time: Eliminate de novo model establishment steps for researchers
- Batch consistency: Standardized production and QC processes to support reproducible results
- Assay flexibility: Compatible with common molecular and cellular biology assays
- Ethically sourced: All materials obtained under approved informed consent frameworks
FAQs
Q: Are CRPC (castration-resistant) models included in the library?
Yes, we maintain models derived from post-endocrine therapy specimens with CRPC-associated molecular features, available for related research upon request.
Q: Do the organoids retain androgen responsiveness?
Selected models derived from hormone-sensitive tumors retain AR expression and show proliferation changes under androgen-manipulated culture conditions, with batch-specific validation data provided.
Q: What downstream assays are compatible with these organoids?
These organoids support viability assays, immunofluorescence, qPCR, targeted sequencing, and pathway activity analysis under standard in vitro research settings.
Q: Can custom models be developed from specific samples?
We accept collaborative custom model development projects based on available sample types and research requirements, subject to ethical approval and feasibility assessment.
Support your prostate cancer research with physiologically relevant, standardized in vitro organoid models.
Contact us to request product specifications, characterization data or discuss custom model collaboration opportunities.
Online Inquiry